Alliance for Clinical Trials in Oncology shared a post on LinkedIn:
”Led by Adrienne Waks of the Dana Farber Cancer Institute, A012303 (ShortStop HER2), is Phase III clinical trial now open for enrollment through the Alliance for Clinical Trials in Oncology.
This study asks if people with early stage HER2 positive breast cancer who have no cancer left (pCR) after neoadjuvant chemotherapy + HER2 targeted therapy, can safely have less treatment after surgery?
Many patients who achieve a pathologic complete response still receive additional therapy after surgery, even though we know pCR is associated with excellent outcomes. ShortStop HER2 aims to determine whether a shorter, less intensive approach can maintain effectiveness while reducing treatment burden, side effects, and cost.
If successful, this study could be practice changing by offering patients:
- A more personalized treatment pathway
- Lower toxicity
- Improved quality of life
- Reduced overtreatment
Learn more or share the trial information here.”
Other Articles About Alliance for Clinical Trials in Oncology On OncoDaily.